TSE:MRVL Stock Latest News
Company AnnouncementsMarvel Biosciences’ MB-204 Shows Broad Efficacy in Autism Mouse Models3w ago
Company AnnouncementsMarvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials1M ago
Company AnnouncementsMarvel Biosciences Targets Up to $3 Million in Private Placement to Advance Lead Drug MB-2041M ago
Company AnnouncementsMarvel Biosciences Grants Deferred Share Units to Independent Directors2M ago
Company AnnouncementsMarvel Biosciences Extends Private Placement Access to Quebec Investors2M ago
Company AnnouncementsMarvel Biosciences’ MB-204 Shows Robust Efficacy in Fragile X Preclinical Study2M agoCompany AnnouncementsMarvel Biosciences Advances MB-204 With High-Bioavailability Pediatric Liquid Formulations6M ago
Company AnnouncementsMarvel Biosciences Advances Pediatric MB-204 Formulations for Neurodevelopmental Disorders6M ago
Company AnnouncementsMarvel Biosciences Lowers Conversion Price on Proposed Debenture Financing6M ago
Company AnnouncementsMarvel Biosciences to Raise Up to $500,000 via Convertible Debenture Offering6M ago
Company AnnouncementsMarvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial6M ago
Company AnnouncementsMarvel Biosciences Wins Alberta Funding to Advance MB-204 Into Phase I Trials7M ago
Company AnnouncementsMarvel Biosciences Taps Novotech to Run Phase I Trial of Lead Neurodrug MB-2047M ago
Company AnnouncementsMarvel Biosciences Backs European Purine Meeting to Bolster A2A Neurology Strategy8M ago
Company AnnouncementsMarvel Biosciences Grants Deferred Share Units to Independent Directors8M ago
Company AnnouncementsMarvel Biosciences Wins NRC IRAP Support for Pediatric Liquid Form of Lead Neurodrug8M ago
Company AnnouncementsMarvel Biosciences Wins Key Japanese Patent for Lead Neurology Drug MB-2049M ago
Company AnnouncementsMarvel Biosciences Issues Deferred Share Units to Directors11M ago
Company AnnouncementsMarvel Biosciences Accelerates Warrant Expiry Amid Strong Shareholder Confidence1y ago